{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:39:54Z","timestamp":1787668794009,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["Z99 CA999999"],"award-info":[{"award-number":["Z99 CA999999"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijrobp.2025.01.022","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T19:42:20Z","timestamp":1738870940000},"page":"407-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Benefit of Short-Term Androgen Deprivation Therapy with Radiation Therapy for Intermediate-Risk Prostate Cancer"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2120-1939","authenticated-orcid":false,"given":"Krishnan R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.01.022_bib0001","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer (version 4.2024). Accessed October 15, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0002","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: An individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0003","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1200\/JCO.2007.15.9699","article-title":"Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy","volume":"26","author":"D'Amico","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0004","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: Results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0005","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ijrobp.2024.08.017","article-title":"Short-term androgen deprivation therapy and high-dose radiotherapy in intermediate-and high-risk localized prostate cancer: Results from the GETUG 14 randomized phase III trial","volume":"120","author":"Demogeot","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0006","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0007","first-page":"41","article-title":"Fixed- and Random-Effects Models","volume":"2022","author":"Kanters","year":"2022"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0008","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0010","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0011","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 5.0. 1. Cochrane Collaboration and","author":"Higgins","year":"2008"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0012","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.21.00855","article-title":"Short androgen suppression and radiation dose escalation in prostate cancer: 12-year results of EORTC trial 22991 in patients with localized intermediate-risk disease","volume":"39","author":"Bolla","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ijrobp.2025.01.022_bib0013","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259","article-title":"Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial","volume":"42","author":"Hennequin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0014","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/cncr.30093","article-title":"PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer","volume":"122","author":"McPartlin","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0015","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0016","first-page":"295","article-title":"Analyzing effect sizes: Random-effects models","volume":"2","author":"Raudenbush","year":"2009","journal-title":"The handbook of research synthesis and meta-analysis"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0017","unstructured":"United States Food and Drug Administration Casodex (Bicalutamide) prescribing information. Updated October 2017. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020498s028lbl.pdf. Accessed August 27, 2024."},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0018","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijrobp.2021.08.031","article-title":"Adding short-term androgen deprivation therapy to radiation therapy in men with localized prostate cancer: Long-term update of the NRG\/RTOG 9408 randomized clinical trial","volume":"112","author":"Jones","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0019","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2020.10.023","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial","volume":"143","author":"Nabid","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0021","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.21.00855","article-title":"Short androgen suppression and radiation dose escalation in prostate cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease","volume":"39","author":"Bolla","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0022","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0023","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","article-title":"Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial","volume":"6","author":"Denham","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0024","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.2015.8577","article-title":"Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"314","author":"D'Amico","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0025","series-title":"Bootstrap methods and their application","author":"Davison","year":"1997"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0026","first-page":"5577","article-title":"Fear of cancer recurrence and PSA anxiety in patients with prostate cancer: A systematic review","volume":"30","author":"James","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0027","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate clinical endpoints for surrogacy in localised prostate cancer: An aggregate meta-analysis","volume":"22","author":"Gharzai","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0028","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.ijrobp.2024.07.131","article-title":"Natural history after likely cure vs. recurrence vs. after ProsTate RadiOtheRapy (RAPTOR): A pooled analysis of more than 13000 Patients from 21 randomized controlled trials","volume":"120","author":"Roy","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0029","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ijrobp.2020.06.011","article-title":"Absolute versus relative benefit of androgen deprivation therapy for prostate cancer: Moving beyond the hazard ratio to personalize therapy","volume":"108","author":"Spratt","year":"2020","journal-title":"International Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0030","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2010.04.004","article-title":"Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer","volume":"80","author":"Krauss","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15083","article-title":"Effect of androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable: A secondary analysis of the RTOG 9408 randomized clinical trial","volume":"3","author":"Zumsteg","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0032","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/cncr.28609","article-title":"The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease","volume":"120","author":"Keane","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0033","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"European urology"},{"key":"10.1016\/j.ijrobp.2025.01.022_bib0034","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.prro.2015.12.005","article-title":"Acute gastrointestinal toxicity and bowel bag dose-volume parameters for preoperative radiation therapy for retroperitoneal sarcoma","volume":"6","author":"Mak","year":"2016","journal-title":"Pract Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:51:47Z","timestamp":1762296707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625000860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0360301625000860"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.022","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Benefit of Short-Term Androgen Deprivation Therapy with Radiation Therapy for Intermediate-Risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}